keyword
MENU ▼
Read by QxMD icon Read
search

Pediatric Acute Lymphoblastic Leukemia

keyword
https://www.readbyqxmd.com/read/29651352/prolonged-survival-of-acute-lymphoblastic-leukemia-with-intrathecal-treatments-for-isolated-central-nervous-system-relapse
#1
Elan Gorshein, Sheila Kalathil, Mecide Gharibo
Acute lymphoblastic leukemia is commonly cured when diagnosed in the pediatric population. It portends a poorer prognosis if present in adult patients. Although adults frequently achieve complete remission, relapse rates are substantial, particularly among the elderly and high-risk populations. In the absence of prophylactic intrathecal chemotherapy, more than half of patients may develop CNS involvement or relapse, which is associated with significant risk for systemic illness. This report describes a patient with acute lymphoblastic leukemia with repeated isolated CNS relapses...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29626196/mutation-methylation-and-gene-expression-profiles-in-dup-1q-positive-pediatric-b-cell-precursor-acute-lymphoblastic-leukemia
#2
Rebeqa Gunnarsson, Sebastian Dilorenzo, Kristina B Lundin-Ström, Linda Olsson, Andrea Biloglav, Henrik Lilljebjörn, Marianne Rissler, Per Wahlberg, Anders Lundmark, Anders Castor, Mikael Behrendtz, Thoas Fioretos, Kajsa Paulsson, Anders Isaksson, Bertil Johansson
High-throughput sequencing was applied to investigate the mutation/methylation patterns on 1q and gene expression profiles in pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL) with/without (w/wo) dup(1q). Sequencing of the breakpoint regions and all exons on 1q in seven dup(1q)-positive cases revealed non-synonymous somatic single nucleotide variants (SNVs) in BLZF1, FMN2, KCNT2, LCE1C, NES, and PARP1. Deep sequencing of these in a validation cohort w (n = 17)/wo (n = 94) dup(1q) revealed similar SNV frequencies in the two groups (47% vs...
March 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29622548/tight-regulation-of-foxo1-is-essential-for-maintenance-of-b-cell-precursor-acute-lymphoblastic-leukemia
#3
Fan Wang, Salih Demir, Franziska Gehringer, Clarissa D Osswald, Felix Seyfried, Stefanie Enzenmüller, Sarah M Eckhoff, Thomas Maier, Karlheinz Holzmann, Klaus-Michael Debatin, Thomas Wirth, Lüder H Meyer, Alexey Ushmorov
The FOXO1 transcription factor plays an essential role in the regulation of proliferation and survival programs at early stages of B-cell differentiation. Here, we show that tightly-regulated FOXO1 activity is essential for maintenance of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Genetic and pharmacological inactivation of FOXO1 in BCP-ALL cell lines produced a strong anti-leukemic effect associated with CCND3 downregulation. Moreover, we demonstrated that CCND3 expression is critical for BCP-ALL survival and overexpression of CCND3 protected BCP-ALL cell lines from growth arrest and apoptosis induced by FOXO1 inactivation...
April 5, 2018: Blood
https://www.readbyqxmd.com/read/29620678/quantitative-ultrasound-of-proximal-phalanxes-in-childhood-acute-lymphoblastic-leukemia-survivors
#4
Antonia De Matteo, Fara Petruzziello, Rosanna Parasole, Antonella Esposito, Argia Mangione, Giovanna Giagnuolo, Giuseppe Menna, Antonio Del Puente
Reduced bone mineral density (BMD) is a well-known complication in childhood acute lymphoblastic leukemia (ALL) survivors; the optimal method to assess BMD is still debated. We studied BMD by quantitative ultrasound (QUS) in 72 ALL survivors, and evaluated any correlation with cumulative doses of steroids and cytotoxic agents. Mean age at diagnosis was 61±45 months, while mean age at QUS was 318.3±129.6 months; mean period of follow-up was 41.2±37.8 months. Mean amplitude-dependent speed of sound z-score was -1...
April 3, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29616457/presepsin-as-a-diagnostic-marker-of-bacterial-infections-in-febrile-neutropenic-pediatric-patients-with-hematological-malignancies
#5
Ahmad Baraka, Marwa Zakaria
Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study...
April 3, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29605883/induction-of-a-central-memory-and-stem-cell-memory-phenotype-in-functionally-active-cd4-and-cd8-car-t-cells-produced-in-an-automated-good-manufacturing-practice-system-for-the-treatment-of-cd19-acute-lymphoblastic-leukemia
#6
Franziska Blaeschke, Dana Stenger, Theresa Kaeuferle, Semjon Willier, Ramin Lotfi, Andrew Didier Kaiser, Mario Assenmacher, Michaela Döring, Judith Feucht, Tobias Feuchtinger
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major therapeutic challenge. Chimeric antigen receptor (CAR) T cells are promising treatment options. Central memory T cells (Tcm) and stem cell-like memory T cells (Tscm) are known to promote sustained proliferation and persistence after T-cell therapy, constituting essential preconditions for treatment efficacy. Therefore, we set up a protocol for anti-CD19 CAR T-cell generation aiming at high Tcm/Tscm numbers. 100 ml peripheral blood from pediatric pre-B ALL patients was processed including CD4+ /CD8+ -separation, T-cell activation with modified anti-CD3/-CD28 reagents and transduction with a 4-1BB-based second generation CAR lentiviral vector...
March 31, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29575541/simultaneous-detection-of-abl1-mutation-and-ikzf1-deletion-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-using-a-customized-target-enrichment-system-panel
#7
M Aoe, H Ishida, T Matsubara, S Karakawa, H Kawaguchi, K Fujiwara, K Kanamitsu, K Washio, K Okada, M Shibakura, A Shimada
INTRODUCTION: Recent clinical outcomes of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) vastly improved owing to tyrosine kinase inhibitor (TKI). However, the genetic status would be different in each case with ABL1 gene mutation or copy number variants (CNVs) such as IKZF1 deletion. In particular, the TKI resistant clone with ABL1 kinase mutation remains problematic. The comprehensive assessment of genetic status including mutation, insertion and deletion (indel) and CNVs is necessary...
March 25, 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29574603/nationwide-survey-of-therapy-related-leukemia-in-childhood-in-japan
#8
Toshihiko Imamura, Takashi Taga, Masatoshi Takagi, Hirohide Kawasaki, Katsuyoshi Koh, Tomohiko Taki, Souichi Adachi, Atsushi Manabe, Yasushi Ishida
Therapy-related leukemia (t-leukemia) is associated with dismal prognosis. Published pediatric t-leukemia data are somewhat outdated and may not reflect recent advances in treatment. We report a retrospective nationwide survey of patients diagnosed between 2000 and 2013 in Japan. We identified 43 patients with pediatric t-leukemia; 33 had t-acute myeloid leukemia (t-AML), eight had t-acute lymphoblastic leukemia (t-ALL) and two had t-acute undifferentiated leukemia. Median age at onset and latency were 12 years and 3...
March 24, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29574396/comparison-of-intensive-pediatric-inspired-therapy-with-non-intensive-therapy-in-older-adults-aged-55-65-years-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia
#9
Josep-Maria Ribera, Olga García, Cristina Gil, Santiago Mercadal, Irene García-Cadenas, Pau Montesinos, Pere Barba, Susana Vives, José González-Campos, Mar Tormo, Jordi Esteve, Aurelio López, María José Moreno, Jordi Ribera, Natalia Alonso, Arancha Bermúdez, María Luz Amigo, Eulàlia Genescà, Daniel García, Ferran Vall-Llovera, Juan Miguel Bergua, Ramon Guàrdia, María Carmen Monteserín, Teresa Bernal, María Calbacho, María Pilar Martínez, Evarist Feliu
BACKGROUND AND OBJECTIVE: The standardization of treatment of older adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) is challenging, especially in the age range of 55-65 years. This study aimed to compare intensive, pediatric-inspired therapy with non-intensive therapy in this population of patients. PATIENTS AND METHODS: The outcomes of 67 patients prospectively included in two consecutive pediatric-inspired intensive protocols (ALL-HR03 and ALL-HR11) from the Spanish PETHEMA Group were compared with those from 44 patients included in a contemporary semi-intensive protocol (ALL-OLD07)...
March 19, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29567885/applicability-of-2008-world-health-organization-classification-system-of-hematolymphoid-neoplasms-learning-experiences
#10
Sushil Modkharkar, Pooja Navale, Pratibha Kadam Amare, Anuradha Chougule, Nikhil Patkar, Prashant Tembhare, Hari Menon, Manju Sengar, Navin Khattry, Shripad Banavali, Brijesh Arora, Gaurav Narula, Siddhartha Laskar, Nehal Khanna, Mary Ann Muckaden, Venkatesh Rangarajan, Archi Agrawal, Tanuja Shet, Sridhar Epari, P G Subramanian, Sumeet Gujral
Background: 2008 World Health Organization (WHO) classification of hematolymphoid neoplasms (HLN) has classified them based on morphology, results of various ancillary techniques, and clinical features.[1] There are no studies looking at the applicability of WHO classification. Aims: The aim of the study was to calculate proportions of all HLN subtypes seen during 1-year period based on 2008 WHO classification of HLN and study applicability and also shortcomings of practices in a tertiary care center in India...
January 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29567586/obesity-and-risk-for-venous-thromboembolism-from-contemporary-therapy-for-pediatric-acute-lymphoblastic-leukemia
#11
Saskia Prasca, Roxana Carmona, Lingyun Ji, Richard H Ko, Deepa Bhojwani, Yasmin A Rawlins, Steven D Mittelman, Guy Young, Etan Orgel
INTRODUCTION: Acute lymphoblastic leukemia (ALL) therapy confers risk for venous thromboembolism (VTE) and associated acute and long-term morbidity. Obesity increases VTE risk in the general population but its impact on ALL therapy-associated VTE is unknown. METHODS: In a retrospective cohort of children treated for ALL between 2008 and 2016 (n = 294), we analyzed obesity at diagnosis (body mass index [BMI] ≥95%) and subsequent development of VTE. A subset participated in two concurrent prospective ALL trials studying body composition via dual-energy X-ray absorptiometry (DXA) (n = 35) and hypercoagulability via thromboelastography (TEG) (n = 46)...
March 2, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29565170/appetite-hormones-in-children-and-adolescents-with-cancer-a-systematic-review-of-observational-studies
#12
Ana Paula Trussardi Fayh, Agnes Denise de Lima Bezerra, Rogerio Friedman
INTRODUCTION: Malnutrition in children with cancer is a significant risk factor for negative outcomes, but in the clinical practice setting, it is difficult to pinpoint which factors operate to cause substantial weight loss and malnutrition in a given patient. Appetite-related hormones like ghrelin and leptin are among possible mediators. However, only few studies have examined the role of these hormones in pediatric patients with cancer to date. Thus, the purpose of this study was to systematically review possible changes in the levels of appetite hormones, specially leptin and ghrelin, in pediatric patients with cancer...
January 19, 2018: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
https://www.readbyqxmd.com/read/29562467/-prognostic-factors-of-pediatric-patients-with-ph-positive-acute-lymphoblastic-leukemia
#13
Y J Xue, J Wu, Y X Zuo, Y P Jia, A D Lu, L P Zhang
Objective: To explore the clinical features and prognostic factors of Ph-positive and/or BCR-ABL positive acute lymphoblastic leukemia (Ph+ ALL) in children. Methods: The clinical data of 68 Ph+ ALL children who were treated at Peking University People's Hospital from December 2006 to December 2016 was retrospectively reviewed. Survival analysis were estimated by Kaplan-Meier method. Univariate analysis was estimated by Log-rank test and Chi-square, and multivariate analysis was estimated by Cox proportional hazards regression model...
March 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29556721/clinical-utility-of-mir-143-mir-182-levels-in-prognosis-and-risk-stratification-specificity-of-bfm-treated-childhood-acute-lymphoblastic-leukemia
#14
Despina Piatopoulou, Margaritis Avgeris, Ioanna Drakaki, Antonios Marmarinos, Marieta Xagorari, Margarita Baka, Apostolos Pourtsidis, Lydia Kossiva, Dimitrios Gourgiotis, Andreas Scorilas
Although childhood acute lymphoblastic leukemia (ALL) is characterized by high remission rates, there are still patients who experience poor response to therapy or toxic effects due to intensive treatment. In the present study, we examined the expression profile of miR-143 and miR-182 in childhood ALL and evaluated their clinical significance for patients receiving Berlin-Frankfurt-Münster (BFM) protocol. Bone marrow specimens from 125 childhood ALL patients upon diagnosis and the end-of-induction (EoI; day 33), as well as from 64 healthy control children undergone RNA extraction, polyadenylation, and reverse transcription...
March 20, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29550628/current-allogeneic-hsct-for-pediatric-all-success-failure-and-future-perspectives-a-single-center-experience-2008-2016
#15
Asaf D Yanir, Caridad A Martinez, Ghadir Sasa, Kathryn Leung, Stephen Gottschalk, Bilal Omer, Nabil Ahmed, Meenakshi Hegde, Jo Eunji, Hao Liu, Helen E Heslop, Malcolm K Brenner, Robert A Krance, Swati Naik
Hematopoietic stem cell transplantation (HSCT) is the only curative option for a subset of patients with high-risk or relapsed Acute Lymphoblastic Leukemia (ALL). Given evolving practices, it is important to continually evaluate outcomes for pediatric ALL following HSCT. Outcomes after HSCT are influenced by the type of donor used as this determines the degree and method of T-cell depletion used, and consequently, specific transplant-related morbidities. We retrospectively analyzed HSCT data from our center for transplants performed between January 2008 and May 2016, comparing outcomes between different donor types...
March 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29550241/low-bioavailability-and-high-immunogenicity-of-a-new-brand-of-e-colil-asparaginase-with-active-host-contaminating-proteins
#16
Priscila Pini Zenatti, Natacha Azussa Migita, Nathália Moreno Cury, Rosângela Aparecida Mendes-Silva, Fabio Cesar Gozzo, Pedro Otavio de Campos-Lima, José Andrés Yunes, Silvia Regina Brandalise
The drug l-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). The native E. colil-asparaginase used in Brazil until recently has been manufactured by Medac/Kyowa. Then a decision was taken by the Ministry of Health in 2017 to supply the National Health System with a cheaper alternative l-asparaginase manufactured by Beijing SL Pharmaceutical, called Leuginase®. As opposed to Medac, the asparaginase that has been in use in Brazil under the trade name of Aginasa®, it was not possible to find a single entry with the terms Leuginase in the Pubmed repository...
March 9, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29536454/insights-of-acute-lymphoblastic-leukemia-with-development-of-genomic-investigation
#17
Heng Xu, Yang Shu
Treatment outcomes for acute lymphoblastic leukemia (ALL), especially pediatric ALL, have greatly improved due to the risk-adapted therapy. Combination of drug development, clinical practice, as well as basic genetic researches has brought the survival rate of ALL from less than 10% to more than 90% today, not only increasing the treatment efficacy but also limiting adverse drug reactions (ADRs). In this review, we summarized the landscape identification of ALL genetic alterations, which provided the opportunity to increase the survival rate and especially minimize the relapse risk of ALL, and highlighted the importance of the development of new technologies of genomic investigation for translational medicine...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29530508/differential-expression-of-cd73-cd86-and-cd304-in-normal-vs-leukemic-b-cell-precursors-and-their-utility-as-stable-minimal-residual-disease-markers-in-childhood-b-cell-precursor-acute-lymphoblastic-leukemia
#18
Łukasz Sędek, Prisca Theunissen, Elaine Sobral da Costa, Alita van der Sluijs-Gelling, Ester Mejstrikova, Giuseppe Gaipa, Alicja Sonsala, Magdalena Twardoch, Elen Oliveira, Michaela Novakova, Chiara Buracchi, Jacques J M van Dongen, Alberto Orfao, Vincent H J van der Velden, Tomasz Szczepański
BACKGROUND: Optimal discrimination between leukemic blasts and normal B-cell precursors (BCP) is critical for treatment monitoring in BCP acute lymphoblastic leukemia (ALL); thus identification of markers differentially expressed on normal BCP and leukemic blasts is required. METHODS: Multicenter analysis of CD73, CD86 and CD304 expression levels was performed in 282 pediatric BCP-ALL patients vs. normal bone marrow BCP, using normalized median fluorescence intensity (nMFI) values...
March 9, 2018: Journal of Immunological Methods
https://www.readbyqxmd.com/read/29527929/notch-signaling-as-a-therapeutic-target-for-acute-lymphoblastic-leukemia
#19
Diana Bellavia, Rocco Palermo, Maria Pia Felli, Isabella Screpanti, Saula Checquolo
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Although the therapy of ALL has significantly improved, the heterogeneous genetic landscape of the disease often causes relapse, which is difficult to treat. Achieving a positive outcome for patients with relapsed or refractory ALL remains a challenging issue. The high prevalence of NOTCH-activating mutations in T-cell acute lymphoblastic leukemia (T-ALL) and the central role of NOTCH signaling in regulating cell survival and growth of ALL provide a rationale for the development of Notch signaling-targeted strategies in this disease...
March 12, 2018: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/29519867/prognostic-impact-of-the-absence-of-biallelic-deletion-at-the-trg-locus-for-pediatric-patients-with-t-cell-acute-lymphoblastic-leukemia-treated-on-the-mrc-ukall2003-trial
#20
Nadine Farah, Amy A Kirkwood, Sunniyat Rahman, Theresa Leon, Sarah Jenkinson, Rosemary E Gale, Katharine Patrick, Jeremy Hancock, Sujith Samarasinghe, David C Linch, Anthony V Moorman, Nicholas Goulden, Ajay Vora, Marc R Mansour
No abstract text is available yet for this article.
March 8, 2018: Haematologica
keyword
keyword
98077
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"